Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis in nodal B cell lymphomas: a high throughput study.

Alexandar Tzankov1, Simone Heiss, Stephanie Ebner

  • 1Institute of Pathology, Medical University of Innsbruck, Innsbruck, Austria. atzankov@uhbs.ch

Journal of Clinical Pathology
|June 23, 2006
PubMed
Summary

Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX2) are expressed in aggressive B cell lymphomas, correlating with microvessel density. Angiogenesis targets should consider lymphoma heterogeneity for effective therapeutic strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab Deruxtecan Induces Complete Pathological Response in Oligometastatic HER2-Mutant NSCLC: Case Report.

JTO clinical and research reports·2026
Same author

Lung nodule detection and potential impact on guideline-based management: a retrospective post-market evaluation of three commercial software systems.

European radiology·2026
Same author

Coordinated immune-epithelial dynamics in the nasal epithelium protect against respiratory virus infection.

bioRxiv : the preprint server for biology·2026
Same author

Reactive and therapy induced bone marrow changes linked to systemic infectious and non-infectious disorders including MAS/HLH report from the European association for haematopathology, Dubrovnik 2024.

Virchows Archiv : an international journal of pathology·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Mast Cells in Acute COVID-19 Patients.

Allergy·2026

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial in tumor growth and progression.
  • Vascular Endothelial Growth Factor (VEGF) and Cyclooxygenase 2 (COX2) are key regulators of angiogenesis.
  • Understanding their role in B cell lymphomas is vital for targeted therapies.

Purpose of the Study:

  • To investigate the biological significance of VEGF, VEGF receptor (Flk-1), and COX2 expression in nodal B cell lymphomas.
  • To correlate these markers with microvessel density (MVD), proliferation (Ki-67), p53 expression, and clinical presentation.
  • To assess the role of angiogenesis in different subtypes of B cell lymphomas.

Main Methods:

  • Immunohistochemical and morphometric analysis of 271 B cell lymphoma specimens using tissue microarrays.

Related Experiment Videos

  • Statistical evaluation including chi-squared test, Spearman's rank correlation, ANOVA, and survival analysis.
  • Assessment of VEGF, Flk-1, COX2, MVD, Ki-67, and p53 expression.

    • Main Results:

    • VEGF, Flk-1, and COX2 were primarily expressed in aggressive lymphomas like Diffuse Large B Cell Lymphomas (DLBCLs).
    • Microvessel density (MVD) was highest in DLBCLs and decreased in Follicular Lymphomas (FLs), Mantle Cell Lymphomas (MCLs), and Small Lymphocytic Lymphomas/Chronic Lymphocytic Leukaemia (SLL/CLLs).
    • VEGF, Flk-1, and COX2 expression correlated with proliferation markers (Ki-67) and p53, but not with clinical parameters or survival.

    Conclusions:

    • Angiogenesis plays a differential role across various B cell lymphomas.
    • Aggressive lymphomas exhibit higher MVD and express potential therapeutic targets VEGF and COX2.
    • Therapeutic strategies targeting angiogenesis must account for the heterogeneity of B cell lymphomas.